Screener
Baxter International BAX Drug Compounding — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Baxter International’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028962
| (in millions) | Three Months Ended March 31, 2026 / U.S. | Three Months Ended March 31, 2026 / International | Three Months Ended March 31, 2026 / Total | Three Months Ended March 31, 2025 / U.S. | Three Months Ended March 31, 2025 / International | Three Months Ended March 31, 2025 / Total |
|---|---|---|---|---|---|---|
| Care & Connectivity Solutions | 315 | 120 | 435 | 316 | 111 | 427 |
| Front Line Care | 198 | 72 | 270 | 202 | 75 | 277 |
| Healthcare Systems & Technologies | 513 | 192 | 705 | 518 | 186 | 704 |
| Injectables & Anesthesia | 180 | 121 | 301 | 195 | 140 | 335 |
| Drug Compounding | — | 320 | 320 | — | 246 | 246 |
| Pharmaceuticals | 180 | 441 | 621 | 195 | 386 | 581 |
| Other | 51 | 39 | 90 | 48 | 30 | 78 |
| Total Baxter | $1,435 | $1,266 | $2,701 | $1,490 | $1,135 | $2,625 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Baxter International's drug compounding — net sales?
- Baxter International (BAX) reported drug compounding — net sales of $320M in Q1 2026.
- How has Baxter International's drug compounding — net sales changed year-over-year?
- Baxter International's drug compounding — net sales increased by 30.1% year-over-year, from $246M to $320M.
- What is the long-term trend for Baxter International's drug compounding — net sales?
- Over 3 years (2021 to 2025), Baxter International's drug compounding — net sales has grown at a 8.2% compound annual growth rate (CAGR), from $901M to $1.14B.
- What does drug compounding — net sales mean?
- This metric represents the total revenue generated from the sale of customized pharmaceutical preparations tailored to meet the specific needs of individual patients or healthcare facilities. It reflects the company's ability to capture market share in the outsourced sterile compounding sector, which provides essential medications that are not commercially available in the required dosage or form. Growth in this segment indicates successful expansion in hospital pharmacy services and the ability to navigate complex regulatory requirements for sterile drug production.
Ask your AI about Baxter International's drug compounding — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude